List of Excipients in Branded Drug GAMMAKED

GAMMAKED Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

GAMMAKED is a 10% human immune globulin product whose commercial differentiation depends more on plasma sourcing, viral-clearance controls, protein stability, supply reliability, and route-of-administration performance than on conventional small-molecule excipient innovation. Its disclosed formulation uses glycine as the principal stabilizing excipient and contains no preservative. The main commercial opportunities are excipient-qualified manufacturing, low-volume and home-infusion presentations, supply-chain resilience, and differentiated immune-globulin delivery systems.

What is GAMMAKED and how is it used?

GAMMAKED is immune globulin injection, human, 10%. It is administered intravenously for primary humoral immunodeficiency and immune thrombocytopenic purpura, and subcutaneously for chronic inflammatory demyelinating polyneuropathy under the approved labeling. The product is a plasma-derived biologic containing polyclonal human immunoglobulin G.

Attribute	GAMMAKED profile
Active ingredient	Human immune globulin, primarily IgG
Strength	10% protein concentration
Routes	Intravenous and subcutaneous administration, according to approved labeling
Principal excipient	Glycine
Preservatives	None disclosed in the product labeling
Source material	Human plasma
Product category	Plasma-derived biologic
Key clinical markets	Primary immunodeficiency, immune thrombocytopenia, CIDP
Regulatory framework	Biologics License Application and postmarketing biologic controls
Substitution framework	Purple Book biologic interchangeability rules, not conventional Orange Book generic substitution

GAMMAKED is not a conventional tablet or injectable small molecule. The formulation must preserve IgG monomer content, limit aggregation, maintain tolerability, and remain compatible with intravenous and subcutaneous administration.

What excipients are used in GAMMAKED?

GAMMAKED uses glycine as the disclosed stabilizing excipient and water for injection as the vehicle. The product does not use a preservative. The labeling identifies an acidic formulation environment and a protein concentration of approximately 10% [1].

Why is glycine commercially important?

Glycine is used in immune-globulin formulations because it can help stabilize proteins during storage and handling without introducing a high ionic burden. For a plasma-derived IgG product, the excipient system must support:

• Low aggregate formation.
• Maintenance of IgG monomer content.
• Tolerability during intravenous infusion.
• Compatibility with subcutaneous administration.
• Stability across refrigerated storage and permitted handling excursions.
• Consistent performance after filling, shipping, and administration.

Glycine is also commercially attractive because it is a relatively simple, well-characterized excipient with established pharmaceutical use. Its low molecular weight and broad supplier base can reduce procurement risk compared with specialized surfactants or novel stabilizers.

What excipients are not disclosed as part of the formulation?

The public label does not identify polysorbate, sorbitol, sucrose, maltose, albumin, or a preservative as formulation components. That distinction matters because excipients used in competing immune-globulin products can affect viscosity, osmolality, route compatibility, immunogenicity risk, and container interaction.

No conclusion should be drawn that a non-disclosed processing aid is absent from the manufacturing process. Product labeling and the complete chemistry, manufacturing, and controls file do not provide the same level of detail.

How does GAMMAKED’s excipient strategy compare with competing immune globulins?

The principal competitive differences are the stabilizer system, concentration, route of administration, infusion volume, viscosity, and manufacturing platform.

Product category	Typical formulation considerations	Commercial relevance
10% intravenous immune globulin	Glycine, sugars, amino acids, or other stabilizers may be used	Competes on tolerability, infusion time, supply, and price
10% subcutaneous immune globulin	Must support repeated small-volume injections and local tissue tolerability	Competes on home use, device compatibility, and patient burden
20% subcutaneous immune globulin	Higher concentration reduces volume per dose	Competes on injection volume and administration frequency
Hyaluronidase-enabled products	Enzyme temporarily increases subcutaneous tissue permeability	Competes on larger-volume administration and convenience
Plasma-derived specialty Ig products	May use distinct stabilizers and purification processes	Competes on source plasma, indication, and supply reliability

GAMMAKED’s glycine-based formulation can be commercially attractive where buyers value a familiar excipient profile and a preservative-free presentation. It is less differentiated if competing products offer materially shorter administration times, higher concentrations, prefilled devices, or more reliable supply.

What formulation patents protect GAMMAKED?

Publicly available product labeling does not establish a complete patent estate for GAMMAKED. Because GAMMAKED is a biologic, exclusivity analysis should separate:

1. Patent protection for the formulation.
2. Manufacturing-process patents.
3. Treatment-method patents.
4. Device or administration patents.
5. Regulatory exclusivity.
6. Any licensed third-party intellectual property.

The label identifies glycine and the general product composition, but it does not provide a complete list of issued patents, claims, patent term adjustments, terminal disclaimers, or licensing rights.

Are GAMMAKED patents listed in the Orange Book?

GAMMAKED should not be analyzed as an ordinary Orange Book-listed small-molecule product. Biologic products are generally tracked through the FDA Purple Book rather than the Orange Book. The relevant regulatory questions are whether a competing product is:

• A biosimilar.
• An interchangeable biosimilar.
• A separately licensed biologic.
• A product approved under a different legal pathway.
• A product subject to patent litigation under the Biologics Price Competition and Innovation Act.

Orange Book-style Paragraph IV certification is not the primary pathway for a biosimilar challenge to GAMMAKED.

When does GAMMAKED lose exclusivity?

The end of commercial protection cannot be determined from the product label alone. For GAMMAKED, effective loss of exclusivity depends on the interaction between patent expiry, biologic regulatory exclusivity, litigation, and the time needed for a competitor to obtain approval and scale plasma supply.

A biologic’s competitive exposure may arise from:

• Expiration of formulation or process patents.
• Expiration of method-of-use patents.
• Expiration of the statutory reference-product exclusivity period.
• Approval of a biosimilar.
• Approval of another immune-globulin product that competes without relying directly on GAMMAKED’s reference product.
• Contract manufacturing or plasma-supply constraints affecting the incumbent.

The BPCIA provides reference-product exclusivity periods and a biosimilar approval pathway, but practical market entry also depends on FDA review, analytical comparability, clinical requirements, manufacturing capacity, and patent resolution [2].

Are there Paragraph IV challenges to GAMMAKED?

A conventional Paragraph IV challenge is not the expected pathway for GAMMAKED because it is a biologic rather than a conventional drug product approved under an abbreviated new drug application. A competitor would normally pursue a biosimilar application under section 351(k) of the Public Health Service Act or seek approval as an independent biologic.

Patent disputes may still arise. Typical claims could cover:

• IgG purification.
• Caprylate or chromatography processing.
• Viral inactivation.
• Glycine-stabilized immune-globulin formulations.
• Protein concentration ranges.
• Subcutaneous administration methods.
• Treatment of CIDP or immune thrombocytopenia.
• Container, fill-finish, or administration systems.

The absence of a publicly identified Paragraph IV case does not establish freedom from patent risk. It indicates that the litigation analysis must use biologic patent and BPCIA records instead.

What is the FDA regulatory status of GAMMAKED?

GAMMAKED is regulated as a prescription biologic. The FDA label identifies indications in primary humoral immunodeficiency, immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy, subject to the specific approved dosage and administration language [1].

The principal regulatory controls include:

• Donor eligibility and plasma testing.
• Pathogen screening.
• Viral reduction and clearance.
• Lot-release testing.
• IgG identity and potency.
• Aggregate and fragment control.
• Sterility and endotoxin testing.
• Container-closure integrity.
• Pharmacovigilance for thrombotic events, renal complications, hemolysis, and hypersensitivity.

The excipient strategy cannot be changed through ordinary product-line management. A material change to glycine concentration, pH, osmolality, protein concentration, container, fill volume, or manufacturing process could require comparability studies and a supplement to the biologics license.

What commercial opportunities exist for GAMMAKED excipients?

1. Qualified glycine supply

The most direct opportunity is not a novel excipient. It is a reliable, pharmaceutical-grade glycine supply chain with tight control of:

• Assay.
• Bioburden.
• Endotoxin.
• Trace metals.
• Residual solvents.
• Particle burden.
• Lot-to-lot variability.

A supplier that can provide dual-site manufacturing, validated change control, and contingency inventory can create value even where the excipient itself is not proprietary.

2. Excipient systems for subcutaneous delivery

Subcutaneous immune globulin places greater demands on local tolerability and injection volume. Commercial opportunities include excipient systems that preserve IgG stability while limiting:

• Injection-site pain.
• Swelling.
• Local inflammation.
• Viscosity.
• Dose volume.
• Protein aggregation after repeated handling.

Any new excipient would face a high regulatory burden. The most realistic near-term opportunity is optimization of established excipients rather than introduction of an untested chemical entity.

3. High-concentration immune globulin

A 20% or higher-concentration formulation could reduce administered volume relative to a 10% product. The development challenge is maintaining acceptable viscosity, stability, syringeability, and subcutaneous tolerability.

A higher-concentration product could compete with conventional 10% products through:

• Fewer injection sites.
• Shorter administration time.
• Lower shipping volume.
• Reduced storage footprint.
• Better compatibility with wearable or infusion devices.

4. Device-compatible formulations

Prefilled syringes, wearable pumps, and home-infusion systems create demand for immune-globulin formulations with controlled viscosity and low particle formation. Commercial value may come from the combination of formulation and device rather than from the excipient alone.

Relevant technical requirements include:

• Low extractables and leachables.
• Stable contact with elastomers and lubricants.
• Reliable syringe delivery force.
• Resistance to agitation.
• Compatibility with extended administration.
• Maintenance of protein quality after device residence.

5. Manufacturing-process excipients

Excipients can improve process recovery, filtration performance, and bulk-hold stability. These applications may support proprietary manufacturing know-how even when the final label discloses only a limited excipient list.

Potential areas include:

• Stabilization during bulk intermediate storage.
• Reduced adsorption to process equipment.
• Improved filtration throughput.
• Lower aggregate formation during concentration.
• Better recovery during fill-finish operations.

Process patents may provide stronger protection than a basic glycine composition claim, provided the claims are technically narrow and supported by comparative data.

How strong is the GAMMAKED patent estate?

The formulation patent position appears difficult to assess from public labeling alone. A simple claim covering immune globulin with glycine would likely face validity and prior-art challenges because glycine-stabilized immunoglobulin formulations are established in the field. Stronger protection would more likely depend on a defined combination of:

• Protein concentration.
• Glycine concentration.
• pH range.
• Aggregate specification.
• Viral-clearance process.
• Subcutaneous dosing regimen.
• Device compatibility.
• Manufacturing sequence.

Patent strength should therefore be evaluated claim by claim rather than by counting patent families. A narrow process claim with demonstrated yield or stability improvement may have greater commercial value than a broad but vulnerable composition claim.

What generic, biosimilar, and competitive entry risks exist?

Biosimilar risk

A biosimilar competitor would need to establish analytical similarity and satisfy FDA requirements for safety, purity, and potency. Immune globulin products present added complexity because they are heterogeneous polyclonal mixtures derived from human plasma.

Competitive barriers include:

• Plasma collection capacity.
• Donor recruitment.
• Fractionation infrastructure.
• Viral-clearance validation.
• Lot consistency.
• Global supply-chain qualification.
• Pharmacovigilance.
• Commercial contracting with hospitals and specialty pharmacies.

These barriers can delay competitive entry even after regulatory approval.

Non-biosimilar competition

GAMMAKED also competes with separately licensed immune-globulin products. A competing product may avoid direct reliance on GAMMAKED’s clinical data while targeting the same indications. This creates commercial pressure independent of formal biosimilar approval.

Supply risk

Plasma-derived products are exposed to collection disruptions, geopolitical restrictions, manufacturing deviations, and demand increases. Supply reliability can be a stronger commercial differentiator than small excipient changes.

What licensing and partnering opportunities exist?

The most credible partnering opportunities are in:

• Pharmaceutical-grade glycine and alternate stabilizer supply.
• Plasma fractionation and contract manufacturing.
• Subcutaneous delivery devices.
• High-concentration immune-globulin formulations.
• Cold-chain logistics.
• Home-infusion services.
• Analytical methods for aggregate, fragment, and potency testing.

A licensing transaction based only on glycine is unlikely to command substantial value because glycine is a well-known excipient. A stronger transaction would combine formulation know-how with validated process performance, device compatibility, or a protected administration method.

Key Takeaways

• GAMMAKED is a 10% human immune globulin biologic with glycine as the principal disclosed stabilizer.
• The product is preservative-free according to its public labeling.
• Its commercial value depends on protein stability, plasma supply, viral safety, manufacturing consistency, and route-of-administration performance.
• GAMMAKED should be analyzed through biologic and Purple Book frameworks, not as a conventional Orange Book generic.
• Paragraph IV is not the primary challenge mechanism; biosimilar approval and biologic patent litigation are more relevant.
• The strongest excipient opportunities are qualified supply, high-concentration formulations, subcutaneous tolerability, device compatibility, and process stabilization.
• A basic glycine composition claim would likely be less defensible than a narrow formulation-process or device-combination claim.
• Public labeling does not establish a complete GAMMAKED patent estate, expiration schedule, or litigation history.

FAQs

Is glycine the only excipient in GAMMAKED?

The public label identifies glycine and water for injection as formulation components. It does not provide the complete manufacturing disclosure that may appear in the confidential chemistry, manufacturing, and controls file.

Can GAMMAKED be substituted automatically with a generic?

No. GAMMAKED is a biologic, so substitution depends on the approval status of a competing biosimilar and, where applicable, an FDA interchangeability determination under the Public Health Service Act.

Would a 20% GAMMAKED formulation require a new approval?

A material increase in protein concentration would generally require regulatory review supported by comparability, stability, manufacturing, safety, and administration data. It would not be treated as a routine excipient change.

What is the most valuable excipient opportunity for immune globulin products?

The highest-value opportunities are usually tied to improved administration, lower viscosity, reduced injection-site reactions, longer stability, or compatibility with home-infusion devices rather than to a commodity excipient alone.

Are immune-globulin formulation patents easy to design around?

Often, yes, if claims cover broadly known stabilizers such as glycine. More difficult design-around issues arise when protection covers a specific process, validated impurity profile, high-concentration formulation, delivery device, or treatment regimen.

References

1. U.S. Food and Drug Administration. (n.d.). GAMMAKED: Immune globulin injection, human, 10% prescribing information.
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
3. U.S. Food and Drug Administration. (2021). Questions and answers on biosimilar development and the BPCI Act.
4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.